

AMENDMENTS TO THE CLAIMS

Listing of Claims:

1. (Currently amended) A monocyte-derived multipotent cell, derived from a monocyte, wherein said monocyte-derived multipotent cell ~~which~~ expresses CD14 and CD34.

2. (Currently amended) The monocyte-derived multipotent cell according to claim 1 ~~, derived from a monocyte, which~~ further expresses expressing CD14, ~~CD34~~, CD45 and type I collagen.

3. (Original) The monocyte-derived multipotent cell according to claim 1 or 2, that can differentiate into mesenchymal cells by a culture under a condition inducing differentiation into mesenchymal tissues.

4. (Original) The monocyte-derived multipotent cell according to claim 3, wherein the mesenchymal cells are osteoblasts, skeletal myoblasts, chondrocytes or adipocytes.

5. (Original) The monocyte-derived multipotent cell according to claim 1 or 2, that can differentiate into myocardial cells by a culture under a condition inducing differentiation into cardiac muscle such as a coculture with cultured myocardial cells.

6. (Original) The monocyte-derived multipotent cell according to claim 1 or 2, that can differentiate into nerve by a culture under a condition inducing differentiation into nerve, such as a coculture with cultured nerve.

7. (Original) The monocyte-derived multipotent cell according to claim 1 or 2, that can differentiate into endothelial cells by a culture under a condition inducing differentiation into endothelium, such as a culture under a condition maintaining endothelial cells.

8. (Original) The monocyte-derived multipotent cell according to claim 1 or 2, that can differentiate into mesodermal cells.

9. (Withdrawn - Currently amended) A method for preparing a monocyte-derived multipotent cell according to claim 1, comprising culturing peripheral blood mononuclear cells (PBMCs) in vitro on fibronectin, and collecting fibroblast-like cells expressing CD14 and CD34.

10. (Withdrawn) The method for preparing a monocyte-derived multipotent cell according to claim 9, comprising culturing in vitro on fibronectin for 5 to 14 days.

11. (Withdrawn - Currently amended) A mesenchymal progenitor, a mesenchymal cell or a mesenchymal tissue induced by culturing the monocyte-derived multipotent cell according to ~~any one of claim~~ claim ~~1~~ 1 ~~[[to 8]]~~ or 2, under a condition inducing differentiation into mesenchymal tissues.

12. (Withdrawn) The mesenchymal progenitor, the mesenchymal cell or the mesenchymal tissue according to claim 11, wherein the mesenchymal cells are osteoblasts, skeletal myoblasts, chondrocytes or adipocyte.

13. (Withdrawn - Currently amended) A myocardial progenitor, a myocardial cell or a myocardial tissue induced by culturing the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2, under a condition inducing differentiation into cardiac muscle such as a coculture with cultured myocardial cells.

14. (Withdrawn - Currently amended) A neural progenitor, a neuron or a nerve tissue induced by culturing the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2, under a condition inducing differentiation into nerve, such as a coculture with cultured neuron.

15. (Withdrawn - Currently amended) An endothelial progenitor, an endothelial cell or an endothelial tissue induced by culturing the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2, under a condition inducing differentiation into endothelium, such as a culture under a condition maintaining endothelial cells.

16. (Withdrawn - Currently amended) A mesodermal progenitor, a mesodermal cell or a mesodermal tissue induced to differentiate from the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2, under a condition inducing differentiation into mesodermal cell or mesodermal tissue, such as a culture under a condition maintaining mesodermal cells.

17. (Withdrawn - Currently amended) A therapeutic agent comprising as active ingredient the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2 and/or

mesodermal progenitors, mesodermal cells and/or mesodermal tissues induced to differentiate from the monocyte-derived multipotent cell.

18. (Withdrawn - Currently amended) A therapeutic agent comprising as active ingredient the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2 and/or neural progenitors, neurons and/or nerve tissues induced to differentiate from the monocyte-derived multipotent cell.

19. (Withdrawn - Currently amended) A treating method comprising administering the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2 and/or mesodermal progenitors, mesodermal cells and/or mesodermal tissues induced to differentiate from the monocyte-derived multipotent cell.

20. (Withdrawn - Currently amended) A treating method comprising administering the monocyte-derived multipotent cell according to ~~any one of claim~~[[s]] 1 [[to 8]] or 2 and/or neural progenitors, neurons and/or nerve tissues induced to differentiate from the monocyte-derived multipotent cell.

21. (New) A monocyte-derived multipotent cell according to claim 1, wherein said monocyte is obtained by culturing peripheral blood mononuclear cells (PBMCs) in vitro on fibronectin, and collecting fibroblast-like cells expressing CD14 and CD34.

22. (New) A method for preparing the monocyte-derived multipotent cell according to claim 21, comprising culturing in vitro on fibronectin for 5 to 14 days.